Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence

Introduction Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence
F. Cantini, D. Goletti ................................................................. 1

Update on the Epidemiology of Tuberculosis in Italy
M. Conversano ................................................................. 4

The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics
G. Delogu, D. Goletti .......................................................... 11

Cellular and Humoral Immune Responses During Tuberculosis Infection:
Useful Knowledge in the Era of Biological Agents
A. Matucci, E. Maggi, A. Vultaggio ........................................... 17

Performance of the Tuberculin Skin Test and Interferon-γ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches
D. Goletti, A. Sanduzzi, G. Delogu ............................................. 24

Diagnostic Accuracy of Chest Radiography for the Diagnosis of Tuberculosis (TB) and Its Role in the Detection of Latent TB Infection: a Systematic Review
R. Piccazzo, F. Paparo, G. Garlaschi ........................................... 32

Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations
F. Iannone, F. Cantini, G. Lapadula ............................................. 41

Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance
F. Cantini, L. Niccoli, D. Goletti ................................................ 47

Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries
F. Cantini, L. Niccoli, D. Goletti ................................................. 56

Tuberculosis Reactivation Risk in Dermatology
L. Pescitelli, F. Ricceri, F. Prignano ........................................... 65

Current Treatment Options for Latent Tuberculosis Infection
M. Bocchino, A. Matarese, A. Sanduzzi ......................................... 71

Restarting Biologics and Management of Patients with Flares of Inflammatory Rheumatic Disorders or Psoriasis During Active Tuberculosis Treatment
F. Cantini, F. Prignano, D. Goletti ............................................. 78

Cost for Tuberculosis Care in Developed Countries: Which Data for an Economic Evaluation?
L. Trieste, G. Turchetti .............................................................. 83